Edition:
India

Achieve Life Sciences Inc (ACHV.OQ)

ACHV.OQ on NASDAQ Stock Exchange Capital Market

1.79USD
2:29am IST
Change (% chg)

$0.04 (+2.29%)
Prev Close
$1.75
Open
$1.73
Day's High
$1.81
Day's Low
$1.73
Volume
9,092
Avg. Vol
183,461
52-wk High
$32.00
52-wk Low
$1.70

Latest Key Developments (Source: Significant Developments)

Achieve Announces Results Of Clinical Study Demonstrating Similar Bioavailability For A New Cytisine Formulation In Fed And Fasted Subjects
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Achieve Life Sciences Inc ::ACHIEVE ANNOUNCES RESULTS OF CLINICAL STUDY DEMONSTRATING SIMILAR BIOAVAILABILITY FOR A NEW CYTISINE FORMULATION IN FED AND FASTED SUBJECTS.ACHIEVE LIFE SCIENCES INC - 3 MG DOSE OF NEW FORMULATION OF CYTISINE WAS VERY WELL TOLERATED.ACHIEVE LIFE SCIENCES INC - STUDY RESULTS DEMONSTRATED BIOEQUIVALENCE WHEN CYTISINE WAS ADMINISTERED WITH OR WITHOUT FOOD.  Full Article

Achieve Life Sciences Inc QTRLY Loss Per Share $1.82
Thursday, 9 Aug 2018 

Achieve Life Sciences Inc ::ACHIEVE REPORTS FINANCIAL RESULTS FOR SECOND QUARTER 2018 AND PROVIDES CYTISINE CLINICAL DEVELOPMENT UPDATE.ACHIEVE LIFE SCIENCES INC QTRLY LOSS PER SHARE $1.82.ACHIEVE LIFE SCIENCES - AS OF JUNE 30, CO'S CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AND RESTRICTED CASH WAS $15.3 MILLION.  Full Article

Achieve Life Sciences Announces Advancement Of Cytisine Development Program Following Meeting With The FDA
Wednesday, 11 Jul 2018 

July 11 (Reuters) - Achieve Life Sciences Inc ::ACHIEVE LIFE SCIENCES ANNOUNCES ADVANCEMENT OF CYTISINE DEVELOPMENT PROGRAM FOLLOWING MEETING WITH THE FDA.ACHIEVE LIFE SCIENCES INC - ACHIEVE PLANS TO INITIATE PHASE 2B TRIAL IN Q4 OF 2018.ACHIEVE LIFE SCIENCES - FOLLOWING RESULTS FROM PHASE 2B OPTIMIZATION TRIAL, CO PLANS TO INITIATE PHASE 3 PROGRAM IN 2019.ACHIEVE LIFE SCIENCES - BASED ON FDA'S RECOMMENDATIONS, PLANS TO CONDUCT PHASE 2B OPTIMIZATION TRIAL IN ABOUT 250 SMOKERS IN U.S..  Full Article

Achieve Announces Patent Granted On Novel Formulation Of Cytisine
Monday, 7 May 2018 

May 7 (Reuters) - Achieve Life Sciences Inc ::ACHIEVE ANNOUNCES PATENT GRANTED ON NOVEL FORMULATION OF CYTISINE.  Full Article

Achieve qtrly loss per share $0.90‍​
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Achieve Life Sciences Inc ::Achieve reports financial results for third quarter 2017.Achieve Life Sciences Inc qtrly loss per share $0.90‍​.  Full Article

Achieve Life Sciences entered into exclusive supply agreement with Sopharma AD
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Sopharma Ad <3JR.BB>:Achieve Life Sciences -‍ co entered into exclusive supply agreement with Sopharma AD for manufacture of Cytisine API and finished tablets​.Achieve Life Sciences Inc - ‍exclusive license agreement provides supply of Cytisine to co for up to 20 years​.Achieve Life Sciences Inc - ‍sopharma agrees to produce CGMP-grade Cytisine for achieve's use in development and commercialization of Cytisine​.  Full Article

ACHIEVE LIFE SCIENCES COMMENCES ADVANCEMENT OF CYTISINE CLINICAL DEVELOPMENT PROGRAM
Wednesday, 4 Oct 2017 

Oct 4 (Reuters) - Achieve Life Sciences Inc ::ACHIEVE LIFE SCIENCES INC - ANNOUNCES COMMENCEMENT OF A MULTI-DOSE STUDY TO EVALUATE BOTH PK AND PD CHARACTERISTICS OF CYTISINE.ACHIEVE LIFE SCIENCES INC - ‍MULTI-DOSE PK/PD STUDY EXPECTED TO BE COMPLETED BY END OF YEAR, WITH DATA EXPECTED BY FIRST-QUARTER OF 2018​.ACHIEVE LIFE SCIENCES-‍DATA ANALYSIS ONGOING,RESULTS EXPECTED BY END OF YEAR IN STUDY FOR EVALUATING EFFECT OF FOOD ON BIOAVAILABILITY OF 3MG CYTISINE​.  Full Article

Robert Schacter reports a 16.7 percent passive stake in Achieve Life Sciences as of Aug 1
Friday, 11 Aug 2017 

Aug 11 (Reuters) - Robert Schacter :Robert Schacter reports a 16.7 percent passive stake in Achieve Life Sciences Inc as of August 1, 2017 - SEC filing‍​.  Full Article